Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes.


As a means of developing therapies that target the pathogenic T cells in multiple sclerosis (MS) without compromising the immune system or eliciting systemic side effects, we investigated the use of T-bet-specific antisense oligonucleotides and small interfering RNAs (siRNA) to silence T-bet expression in autoreactive encephalitogenic T cells and evaluated the biological consequences of this suppression in experimental autoimmune encephalomyelitis, a model for MS. The T-bet-specific AS oligonucleotide and siRNA suppressed T-bet expression, IFNgamma production, and STAT1 levels during antigen-specific T cell differentiation. In vitro suppression of T-bet during differentiation of myelin-specific T cells and in vivo administration of a T-bet-specific antisense oligonucleotide or siRNA inhibited disease. T-bet was shown to bind the IFNgamma and STAT1 promoters, but did not regulate the IL-12/STAT4 pathway. Since T-bet regulates IFNgamma production in CD4(+) T cells, but to a lesser extent in most other IFNgamma-producing cells, T-bet may be a target for therapeutics for Th1-mediated diseases.

6 Figures and Tables

Citations per Year

775 Citations

Semantic Scholar estimates that this publication has 775 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{LovettRacke2004SilencingTD, title={Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes.}, author={Amy E. Lovett-Racke and Anne E Rocchini and Judy Choy and Sara C Northrop and Rehana Z. Hussain and Robert B Ratts and Devanjan Sikder and Michael Karl Racke}, journal={Immunity}, year={2004}, volume={21 5}, pages={719-31} }